Kevin Judice is CEO at DICE Therapeutics, Inc. (DICE). They have made 1 open-market trade across 1 company since 2023, most recently 2023-08-09.
CIK 0001638944
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| DICE | 799,685 | $38.0M |
Shares reported on the most recent Form 4, priced at the 2023-05-05 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DICE | SELL | 2023-05-03 | 2023-05-05 | $36.50 | $500K | -11.9% | -18.3% | +25.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.